PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (PROCEPT BioRobotics or the Company), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, has announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of US$91 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately US$175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company’s common stock at the public offering price, less underwriting discounts and commissions. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The offering is expected to close on or about October 31, 2024, subject to customary closing conditions.

Latham & Watkins advised PROCEPT BioRobotics in the offering with a capital markets team led by Orange County partners Shayne Kennedy and Drew Capurro, with associates Jacob Walsh, Caitlin Nguyen, and Ivana Valdez. Advice was also provided on tax matters by Bay Area partner Grace Lee, with associates Rasha Suleiman and Dennis Poehland; on regulatory matters by Bay Area partner Betty Pang, Washington, D.C. partner Elizabeth Richards, and counsel Chad Jennings, with associate Meryl Bartlett; on IP matters by San Diego partner Christopher Hazuka, with associate Mizuna Sekine; and on data privacy matters by Bay Area partner Heather Deixler, with associate Sarah Zahedi.